Agreed. It is very clear that this is not a re-negotiation but...

Agreed. It is very clear that this is not a re-negotiation but simply a following of the original terms of the agreement. Clearly the original terms included time to analyse the data, but which data that is has never been released.

If we take Si's original ' in a few weeks ' quote, that kind of gels with time to analyse the 3 month data after it's released. But it may also be the case that the specific type of data was never mentioned and simply secondary endpoints was. Novartis in that case could be stringing the company along to the 6 and 12 month secondary data points also. Why would they do that? Because they will likely get feedback from the FDA on what the next trial needs to look like in the interim - or even if some kind of immediate access would be granted to under 65's. That would allow Novartis to cost the rollout significantly more accurately than before any meeting with the FDA.

The third option is that Novartis is not content with the data provided yet. I recall Si mentioning that mesoblast receive the data, they then analyse it, and then they release the analysed dataset to Novartis for them to look at. It could be the case that Novartis are simply asking for the ' other pieces' of data out of DD, since MSC therapy is not their area of expertise.